A Randomized Phase II Trial of ATN-224 in Combination With Temozolomide or Temozolomide Followed by ATN-224 in Patients With Advanced Melanoma
According to the National Cancer Institute PDQ database, advanced melanoma is refractory to
most standard systemic therapy, and all newly diagnosed patients should be considered
candidates for clinical trials. Although advanced melanoma is relatively resistant to
therapy, several biologic response modifiers and cytotoxic agents have been reported to
produce objective responses. Once melanoma is metastatic, treatments are palliative rather
than curative. In spite of many attempts at multimodality therapy, the prognosis in this
disease remains poor. Further agents are needed if progress is to be made with melanoma
treatment.
ATN-224 is an orally active, small molecule that has been shown in cellular and animal
models to be antiangiogenic and to have activity against melanoma cell lines. Clinical
studies with a similar agent (ammonium tetrathiomolybdate) indicate that the agent can be
administered continuously on a daily basis for years in some patients. ATN-224 has the
potential to affect the progression of melanoma by mechanisms that include both
antiangiogenic and antitumor pathways. Temozolomide, a commonly used agent for melanoma,
also has a tolerable profile.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
24-week progression-free survival of the combination of temozolomide with ATN 224 and of temozolomide alone
Gilad Gordon, MD
Study Director
United States: Food and Drug Administration
ATN-224-008
NCT00383851
September 2006
September 2008
Name | Location |
---|---|
Arizona Cancer Center | Tucson, Arizona 85724 |
Florida Cancer Specialists | Fort Myers, Florida 33901 |
Mary Crowley Medical Research Center | Dallas, Texas 75246 |
University of Colorado Health Science Center | Aurora, Colorado 80010-0510 |
Hematology and Oncology Specialists, LLC | New Orleans, Louisiana 70115 |
Cancer Center of the Carolinas | Greenville, South Carolina 29615 |
Center for Cancer and Blood Disorders | Bethesda, Maryland 20817 |
Billings Clinic | Billings, Montana 59107-7000 |
Chattanooga Oncology and Hematology Associates | Chattanooga, Tennessee 37404 |
Tennessee Oncology | Nashville, Tennessee 37203 |
Oncology Hematology Care | Cincinnati, Ohio 45242 |
The Angeles Clinic | Santa Monica, California 90404 |
Pacific Oncology and Hematology | Encinitas, California 92024 |
Hematology - Oncology Group of Orange, Inc. | Orange, California 92868 |
UCI Chao Family Comprehensive Cancer Center | Orange, California 92868 |
The Harry and Jeanette Weinberg Cancer Institute at Franklin Square | Baltimore, Maryland 21237 |
Mountainside Hospital Cancer Center - The Melanoma Center | Montclair, New Jersey 07042 |